nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-1F0A7A81·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Psychiatry and Mental health·Basis: Full text·Type: Observational cohort study

Enhanced sensitivity to plasma p-tau217 with proper names recall in the preclinical Alzheimer's cognitive composite.

He et al.He, Langhough, Jonaitis et al.·2026·Brain communications·10.1093/braincomms/fcag163 ↗

Primary claim

the proper name enhanced-PACC, especially the parsimonious PACC3_PN, demonstrated the steepest decline-6.4-19% faster than the traditional and animal fluency-appended versions.

Tentative · ranked slopes have overlapping confidence intervals and were not directly compared across the correlated composites
In brief

Proper-name recall offers a promising parsimonious PACC refinement, but separate overlapping slope estimates do not establish superiority over existing composites.

ReliabilityNo concerns4 of 4 checks completeSee what was checked ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

A pivotal debate in Alzheimer's disease (AD) revolves around the clinical utility of a purely biomarker-based diagnostic framework, making it imperative to identify early functional signs that are both clinically meaningful and sensitive to biological biomarkers in the preclinical stages. While the development of the Preclinical Alzheimer's Cognitive Composite (PACC) addresses this need, its lack of language-specific markers might limit its sensitivity, given that language deficits are among the earliest manifestations of AD. To address this limitation, we developed PACC variants incorporating proper names delayed recall, a novel lexical-semantic marker robustly linked to PET and CSF biomarkers. We analysed 824 dementia-free participants (mean age ≈ 62 at baseline) from the Wisconsin Registry for Alzheimer's Prevention, stratifying them by plasma phosphorylated tau 217 (p-tau217) levels (using established amyloid PET positivity cut-offs: negative [<0.40 pg/mL; N = 539], intermediate [0.40-0.63 pg/mL; N = 163], positive [>0.63 pg/mL; N = 122]). We constructed six PACC variants: (1) traditional PACC4 (Rey Auditory Verbal Learning Test immediate learning, Logical Memory II [LM II; delayed recall], Digit Symbol, Mini-Mental State Examination [MMSE]); (2) PACC3 (excluding MMSE to mitigate ceiling effects); (3-4) PACC4_PN and PACC3_PN, replacing LM II's total score with proper-name recall; and (5-6) PACC4 + VF and PACC3 + VF, adding animal fluency. Cognitive composites were calculated as the equally weighted sum of component z-scores. We compared PACC variants'sensitivity (i.e. longitudinal decline rates) associated with plasma p-tau217, using linear mixed models adjusted for age, gender, literacy and practice (total visits minus one). We showed individuals with positive plasma p-tau217 status exhibited significantly faster cognitive decline across all PACCs. Notably, the proper name enhanced-PACC, especially the parsimonious PACC3_PN, demonstrated the steepest decline-6.4-19% faster than the traditional and animal fluency-appended versions. Our optimized measure offers critical advantages in clinical utility: an 82% reduction in scoring burden for clinicians (9-point proper names versus 50-point total LM score), finer semantic memory granularity within an episodic memory task and enhanced sensitivity to AD biomarkers. Our findings position proper name-enhanced PACC as a clinically practical tool for tracking longitudinal cognitive trajectories, highlighting proper names delayed recall as a sensitive marker due to AD-type brain changes. Future work will validate its utility for trial enrichment and clinical screening.

Key Claims

Primary finding · Tentative

the proper name enhanced-PACC, especially the parsimonious PACC3_PN, demonstrated the steepest decline-6.4-19% faster than the traditional and animal fluency-appended versions.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

ranked slopes have overlapping confidence intervals and were not directly compared across the correlated composites

Abstract; Results, Table 3
Quote verified
Secondary · Well-supported

individuals with positive plasma p-tau217 status exhibited significantly faster cognitive decline across all PACCs.

all six models report significant p-tau217-positive by age interactions in the same longitudinal cohort

Abstract; Results, paragraph 1 and Figure 1
Quote verified
Secondary · Tentative

Our optimized measure offers critical advantages in clinical utility: an 82% reduction in scoring burden for clinicians (9-point proper names versus 50-point total LM score)

score-range arithmetic does not directly measure scoring time, workflow burden, or clinical utility

Abstract; Discussion, practical-advantages paragraph
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Practical item-level composite refinement

The paper tests a focused nine-item proper-name subscore already embedded in Logical Memory rather than requiring an entirely new assessment. This gives the proposed refinement a plausible implementation pathway in datasets with item-level records.

↳ Language Tasks and Measures; Composite Construction

#methodological rigour

Transparent comparison across six composites

Table 3 reports coefficients, confidence intervals and β/SE values for all six PACC variants, allowing the numerical ranking and percentage calculations to be inspected directly.

↳ Results, Table 3

#positioning

Direct engagement with competing approach

The discussion compares proper-name recall with category verbal fluency and considers the WRAP cohort’s use of a single animal category as an alternative explanation for the difference.

↳ Discussion, paragraph 3

Limitations

#methodological rigour

Superiority lacks a direct statistical test

The central claim rests on ranked point estimates and β/SE values from separate models. Table 3 shows heavily overlapping confidence intervals, and no uncertainty estimate for the differences between correlated composite slopes is reported.

↳ Results, Table 3; Discussion, limitations paragraph

#contribution

Practical utility remains unmeasured

The 82% burden reduction is calculated from score ranges rather than observed scoring time, workflow demands or inter-rater reliability. Claims about clinical feasibility and maximized rater reliability therefore exceed the reported operational evidence.

↳ Abstract; Discussion, practical-advantages paragraph

#positioning

Limitations do not moderate conclusions

The discussion acknowledges overlapping confidence intervals and the need for independent validation, but still describes the measure as “optimal” and an “ideal” endpoint. This leaves the conclusion stronger than the limitations support.

↳ Discussion, paragraphs 1 and 6; Conclusion

Does this match your read? Add your assessment ↓

Nabu Commentary

The six-composite analysis provides a clear within-WRAP comparison and consistently links positive p-tau217 status with faster decline. The central ranking is less secure because Table 3 presents separate, overlapping estimates without directly testing differences between composites. The paper also equates a smaller scoring range with reduced clinical burden despite reporting no timing or reliability study. Contextual engagement is substantive, but the conclusion retains “optimal” and “ideal” language after acknowledging the confidence-interval overlap and need for external validation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.0±0.2

Contribution
3.3

The paper makes a useful incremental contribution by substituting proper-name recall for total Logical Memory delayed recall and benchmarking six PACC variants against plasma p-tau217. Its novelty is constrained by earlier proper-name studies and the absence of a direct statistical demonstration that the new composites are superior.

Introduction, paragraphs 3–5; Composite Construction; Results, Table 3

We also examined whether a proper name–enhanced PACC performs comparably or better than existing PACC versions incorporating category verbal fluency.

Methodological Rigour
2.9

The longitudinal cohort, standardized composites and mixed-effects models support within-cohort associations, but the central composite comparison lacks an inferential test and uses most-recent p-tau217 status across earlier cognitive observations. Selection from 1,751 to 824 participants and limited assessment of the nine-item measure add uncertainty.

Methods, Participants and Statistical Analysis; Results, Table 3

Sensitivity to plasma p-tau217 was compared across PACC variants utilizing β estimates.

Reporting
3.2

The study question, six composite definitions and numerical results are presented in a traceable sequence. Terms such as “outperformed,” “optimal” and “ideal” nevertheless imply established comparative superiority despite overlapping confidence intervals and no direct difference test.

Abstract; Results, Table 3; Discussion, paragraphs 1–2; Conclusion

Both outperformed the original... and verbal fluency-appended PACCs.

Positioning
2.8

The paper directly engages prior PACC and verbal-fluency work and discusses several cohort and test-form limitations. Its acknowledgment of overlapping confidence intervals is not carried through to conclusions that retain “optimal” and “ideal” endpoint language, activating the binding limitation-handling ceiling.

Discussion, paragraphs 3 and 6; Conclusion

We acknowledge that the overlapped confidence intervals for β estimates limit our generalizability beyond the WRAP cohort.

Reliability

No concerns4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyClean

No supplied-text evidence establishes a citation irregularity or another research-conduct finding.

Ethics approval: declared · Data availability: declared · Code availability: declared

Reference IntegrityClean

44 references in manuscript 44 of 44 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceMethodological
Route to useNamed
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The composite's superior sensitivity was demonstrated only in observational longitudinal data from a single risk-enriched cohort, and the authors themselves call for validation in independent diverse populations.

From the paper
“this optimized PACC_PN can be seamlessly applied to both retrospective datasets with item-level entries and future studies, streamlining its adoption in research and routine practice”

The paper names who would use the composite (clinicians in high-demand clinical settings, trial teams for enrichment and screening) and what for, without specifying a concrete decision protocol.

Pathway

Clinicians and Alzheimer's prevention trial teams could adopt the proper name-enhanced PACC, paired with plasma p-tau217, as a streamlined cognitive endpoint for early detection and trial enrichment.

Barrier

Findings rest on one cohort with overlapping confidence intervals between composites, so independent validation in demographically diverse populations is needed before clinical adoption.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial

    Wang, Xu, Xu, et al. · 2026 · Clinical medicine

    Primary claim

    no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP and intensive treatment

    Well-supported
    Evidence Score
    4.1±0.1
    Reliability
    Caveats
  2. Smoking and dementia risk: an updated systematic review and meta-analysis of 61 prospective cohort studies and implications for tobacco control

    Mario Siervo, Jacob Brain, Sarah Beasley, et al. · 2026 · Health sciences

    Primary claim

    Current smoking was associated with increased risk of all-cause dementia (RR 1.31 [95% CI 1.23–1.39]; number of studies (k) = 39), Alzheimer's disease (1.40 [1.08–1.80]; k = 15), and vascular dementia (1.52 [1.20–1.93]; k = 9).

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  3. Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    2026 · Clinical medicine

    Primary claim

    decreased ACD was associated with greater AD pathological burden

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →